Business

Mass. Movers

FDA report lifts Aegerion drug

istockphoto.com

Advertisement

Aegerion Pharmaceuticals Inc. shares jumped Monday after Food and Drug Administration medical reviewers said the Cambridge firm’s proposed drug to treat a rare genetic disorder that causes high cholesterol is effective at reducing it, but there is a potential to cause liver damage. The drug, lomitapide, will be reviewed on Wednesday by a panel of non-FDA medical specialists, which will make recommendations to the agency about whether lomitapide should be approved.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com